Sodium oxybate versus midazolam for end-of-life continuous deep sedation: a randomised controlled trial
This first end-of-life randomised controlled trial comparing midazolam with another sedative suggests that sodium oxybate may offer more stable continuous deep sedation, with fewer fluctuations in sedation depth. These findings support the potential for improving patient comfort in this specific context.
Authors
- Gaëtan Saudemont
- Didier Payen (ORCID: https://orcid.org/0000-0002-5242-6543)
- Pierre-Henri Jacquin (ORCID: https://orcid.org/0000-0002-6366-4344)
- Céline Dugourd
- Jean-François Ciais
- Frédéric Berthier
- Alexiane Decorbez
- Amélie Gac Marrec
Institutions
- Centre National de la Recherche Scientifique (FR)
- Aix-Marseille Université (FR)
- Princess Grace Hospital Centre (MC)
- Centre Hospitalier Universitaire de Nice (FR)
Publication Details
- Journal
- BMJ Supportive & Palliative Care
- Published
- 2025-12-21
- DOI
- https://doi.org/10.1136/spcare-2025-005747
- Primary Topic
- Palliative Care and End-of-Life Issues
- Type
- article
- Field-Weighted Citation Impact
- 0.00